Skip to main content

adakitug

Generic: Adakitug

adakitug: 5 clinical trials tracked.

adakitug evidence translation

What we can confirm

5 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about adakitug, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence6 indications · 1 study sponsors
Clinical Trials (5)

Phase I Study Investigating the Safety of Stereotactic Body Radiotherapy (SBRT) With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

NCT04572451·Phase 1
Active, not recruiting

Primary endpoint: Rate of Dose Limiting Toxicities (DLT)

Interventionalopen50 targetStarted 2021-11Completion 2027-082 sites · United StatesYana Najjar

Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Cancer Patients Undergoing Surgery

NCT04848116·Phase 2
Active, not recruiting

Primary endpoint: Safety of neoadjuvant Nivolumab in combination with HuMax

Interventionalopen24 targetStarted 2021-04Completion 2030-111 site · United StatesSidney Kimmel Comprehensive Cancer Center at Johns Hopkins

A Phase 1/2 Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

NCT03400332·Phase 1/Phase 2·BMY
Completed

Primary endpoint: Number of Participants Experiencing Adverse Events (AEs) - Part 1

InterventionalRandomizedquadruple281 enrolledStarted 2018-02Completion 2025-1250 sites · Australia, Belgium, Canada, France…Bristol-Myers Squibb

Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer (Amended Protocol of: Nivolumab, Ipilimumab and COX2-inhibition in Early Stage Colon Cancer: an Unbiased Approach for Signals of Sensitivity: The NICHE TRIAL)

NCT03026140·Phase 2
Recruiting

Primary endpoint: Incidence of adverse events during the treatment and follow-up (safety)

InterventionalRandomizedopen353 targetStarted 2017-03Completion 2032-036 sites · NetherlandsThe Netherlands Cancer Institute

A Platform Study of Combination Immunotherapy for the Neoadjuvant and Adjuvant Treatment of Patients With Surgically Resectable Adenocarcinoma of the Pancreas

NCT02451982·Phase 2
Active, not recruiting

Primary endpoint: IL17A expression

InterventionalRandomizedopen76 targetStarted 2016-03Completion 2026-091 site · United StatesSidney Kimmel Comprehensive Cancer Center at Johns Hopkins